Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

Georgia L. Wiesner, MD, MS
Published: Wednesday, Feb 24, 2016



Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

In this disease, there is a molecular signature located in the colon tumor itself, allowing for  molecular testing, explains Wiesner. Molecular testing, along with family history, can be used by an oncologist to determine if a patient should be seen by a geneticist.  

  For patients who are reluctant to go to a geneticist, Wiesner suggests pointing out two key benefits. First, genetic testing can help determine which treatment methods will be best for that particular patient. Secondly, genetic testing can determine if the cancer is inherited, which may help other family members of the patient understand their risks.   



Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

In this disease, there is a molecular signature located in the colon tumor itself, allowing for  molecular testing, explains Wiesner. Molecular testing, along with family history, can be used by an oncologist to determine if a patient should be seen by a geneticist.  

  For patients who are reluctant to go to a geneticist, Wiesner suggests pointing out two key benefits. First, genetic testing can help determine which treatment methods will be best for that particular patient. Secondly, genetic testing can determine if the cancer is inherited, which may help other family members of the patient understand their risks.   


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x